A phase II, randomised placebo-controlled, evaluator-blinded study of the safety and efficacy of a product for the treatment of children with moderate to severe atopic dermatitis
DEC-NET Serial number GB261
Published online29/06/2004 17.18.00
Last updated02/08/2005 13.12.46
Other protocol ID numberN0012128238
This trial has been approved by an ethics committee
Current trial statusOpen (actively recruiting new participants)
Major Disease
(ICD9 class)		OTHER ATOPIC DERMATITIS
Experimental drug
N/A
GenderBoth
Age (range)2 to 11 years

Eligibility criteria
Inclusion criteria
Children with moderate to severe atopic dermatitis
Exclusion criteria
informed consent not been given Children who will not stick to the protocol

Trial design/methodology
Phase2
Kind of studyEfficacy
Safety
DesignControlled
Randomised
Blinded
Single blind
Purpose of study
To evaluate the effects of the product on the extent and severity of atopic dermatitis
Primary outcomes
To evaluate the effects of the product on the extent and severity of atopic dermatitis
Summary of study design, objectives, and ongoing research findings
Randomised controlled trial; Random allocation (A) treatment for atopic dermatitis (B) Placebo
Principal investigator
NameProf J Harper
InstitutionGreat Ormond Street Hospital
Postal addressDermatology, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
CityLondon
CountryUNITED KINGDOM
Phone020 7405 9200
Fax
E-mailHarpeJ@gosh.nhs.uk


Sponsor name
Commercial Funder (Industry)

ISRCTN  EudraCT